Logo image of CERS

CERUS CORP (CERS) Stock Price, Quote, News and Overview

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.51  +0.13 (+9.42%)

After market: 1.55 +0.04 (+2.65%)

CERS Quote, Performance and Key Statistics

CERUS CORP

NASDAQ:CERS (6/6/2025, 8:00:00 PM)

After market: 1.55 +0.04 (+2.65%)

1.51

+0.13 (+9.42%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
Statistics
52 Week High2.54
52 Week Low1.12
Market Cap288.65M
Shares191.16M
Float182.59M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/amc
IPO01-31 1997-01-31


CERS short term performance overview.The bars show the price performance of CERS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

CERS long term performance overview.The bars show the price performance of CERS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CERS is 1.51 USD. In the past month the price increased by 11.03%. In the past year, price decreased by -15.17%.

CERUS CORP / CERS Daily stock chart

CERS Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ALC ALCON INC 29.26 43.87B
COO COOPER COS INC/THE 18.64 14.46B
ALGN ALIGN TECHNOLOGY INC 19.36 13.09B
SOLV SOLVENTUM CORP 12.58 12.95B
LNTH LANTHEUS HOLDINGS INC 12.32 5.64B
MMSI MERIT MEDICAL SYSTEMS INC 26.69 5.63B
BLCO BAUSCH + LOMB CORP 24.38 4.14B
HAE HAEMONETICS CORP/MASS 15.42 3.38B
ICUI ICU MEDICAL INC 19.06 3.27B
XRAY DENTSPLY SIRONA INC 9.49 3.18B
UFPT UFP TECHNOLOGIES INC 29.06 1.83B
NEOG NEOGEN CORP 13.71 1.13B

About CERS

Company Profile

CERS logo image Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 281 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Company Info

CERUS CORP

1220 Concord Avenue

Concord CALIFORNIA 94520 US

CEO: William M. Greenman

Employees: 622

CERS Company Website

CERS Investor Relations

Phone: 19252886000

CERUS CORP / CERS FAQ

What is the stock price of CERUS CORP today?

The current stock price of CERS is 1.51 USD. The price increased by 9.42% in the last trading session.


What is the ticker symbol for CERUS CORP stock?

The exchange symbol of CERUS CORP is CERS and it is listed on the Nasdaq exchange.


On which exchange is CERS stock listed?

CERS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CERUS CORP stock?

10 analysts have analysed CERS and the average price target is 4.76 USD. This implies a price increase of 215.23% is expected in the next year compared to the current price of 1.51. Check the CERUS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CERUS CORP worth?

CERUS CORP (CERS) has a market capitalization of 288.65M USD. This makes CERS a Micro Cap stock.


How many employees does CERUS CORP have?

CERUS CORP (CERS) currently has 622 employees.


What are the support and resistance levels for CERUS CORP (CERS) stock?

CERUS CORP (CERS) has a support level at 1.34 and a resistance level at 1.67. Check the full technical report for a detailed analysis of CERS support and resistance levels.


Is CERUS CORP (CERS) expected to grow?

The Revenue of CERUS CORP (CERS) is expected to grow by 24.23% in the next year. Check the estimates tab for more information on the CERS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CERUS CORP (CERS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CERUS CORP (CERS) stock pay dividends?

CERS does not pay a dividend.


When does CERUS CORP (CERS) report earnings?

CERUS CORP (CERS) will report earnings on 2025-07-30, after the market close.


What is the Price/Earnings (PE) ratio of CERUS CORP (CERS)?

CERUS CORP (CERS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).


What is the Short Interest ratio of CERUS CORP (CERS) stock?

The outstanding short interest for CERUS CORP (CERS) is 4.84% of its float. Check the ownership tab for more information on the CERS short interest.


CERS Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CERS. When comparing the yearly performance of all stocks, CERS is a bad performer in the overall market: 73.52% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CERS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CERS. Both the profitability and financial health of CERS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CERS Financial Highlights

Over the last trailing twelve months CERS reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 33.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.16%
ROE -34.14%
Debt/Equity 1.17
Chartmill High Growth Momentum
EPS Q2Q%20%
Sales Q2Q%12.7%
EPS 1Y (TTM)33.33%
Revenue 1Y (TTM)7.86%

CERS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to CERS. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of -20.55% and a revenue growth 24.23% for CERS


Ownership
Inst Owners76.25%
Ins Owners4.57%
Short Float %4.84%
Short Ratio7.34
Analysts
Analysts80
Price Target4.76 (215.23%)
EPS Next Y-20.55%
Revenue Next Year24.23%